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Objective: To characterize the incidence, type, and risk factors of severe infections (SI) in
patients with autoimmune kidney diseases treated with rituximab (RTX).
Methods: We conducted a multicenter retrospective cohort study of adult patients with
immune-related kidney diseases treated with at least one course of RTX between 2015
and 2019. As a part of the ABCDE Registry, detailed data on RTX application and SI were
collected. SI were defined by Common Terminology Criteria for Adverse Events v5.0 as
infectious complications grade 3 and above. Patients were dichotomized between
“nephrotic” and “nephritic” indications. The primary outcome was the incidence of SI
within 12 months after the first RTX application.
Results: A total of 144 patients were included. Twenty-five patients (17.4%) presented
with SI, mostly within the first 3 months after RTX administration. Most patients in the
nephritic group had ANCA-associated vasculitis, while membranous nephropathy wasorg October 2021 | Volume 12 | Article 7607081
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Frontiers in Immunology | www.frontiersin.the leading entity in the nephrotic group. Respiratory infections were the leading SI (n= 10,
40%), followed by urinary tract (n=3, 12%) and gastrointestinal infections (n=2, 8%). On
multivariable analysis, body mass index (BMI, 24.6 kg/m2 versus 26.9 kg/m2, HR: 0.88;
95%CI: 0.79-0.99; p=0.039) and baseline creatinine (HR: 1.25; 95%CI: 1.04-1.49;
p=0.017) were significantly associated with SI. All patients in the nephritic group (n=19;
100%) who experienced a SI received oral glucocorticoid (GC) treatment at the time of
infection. Hypogammaglobulinemia was frequent (58.5%) but not associated with SI.
Conclusions: After RTX administration, impaired kidney function and lower BMI are
independent risk factors for SI. Patients with nephritic glomerular diseases having
concomitant GC treatment might be at higher risk of developing SI.Keywords: rituximab, infections, glomerular disease, vasculitis, lupus, nephrotic, nephriticINTRODUCTION
Severe infections (SI) are a major cause of morbidity and mortality
in patients with kidney disease. In particular, glomerulopathies,
either primary forms or secondary to systemic disorders, exhibit a
heightened risk for such complications, which is determined by the
underlying disease but to a major extent a direct consequence of
immunosuppressive therapy.
Rituximab (RTX), a chimeric monoclonal antibody directed
against the B cell CD20 antigen, was initially approved for the
treatment of hematologic malignancies and subsequently for
rheumatoid arthritis. In 2010, its label was expanded for the
treatment of ANCA-associated vasculitis (AAV). In parallel, it
has become an important off-label agent in the treatment of
various forms of autoimmune kidney diseases, such as primary
membranous nephropathy (MN), minimal change disease
(MCD), and immune-mediated forms of focal segmental
glomerulosclerosis (FSGS). While efficacy data of RTX in most
glomerular pathologies are still limited to observational studies,
several randomized controlled trials (RCT) investigating RTX in
MN have recently been published (1–3).
Although the safety profile of RTX is considered favorable, SI
can occur during and after anti-CD20 therapy. While few
infectious complications were reported in recent key trials, a
French study, involving 98 individuals with various types of
glomerulopathies treated with RTX, noted infectious episodes in
a quarter of patients; cumulative RTX dose and kidney failure
were identified as independent risk factors (4). Generally,
infectious complications appear to be mainly determined by
the indication of RTX, i.e. the underlying disease, individual
patient characteristics, and concurrent therapy.
In a large, contemporary multicenter cohort, we assessed
incidence, type and risk factors for SI in patients treated with
rituximab. Moreover, we wanted to investigate whether SI differ
between “nephrotic “(e.g. MN, MCD, FSGS) and “nephritic”
(AAV, lupus nephritis (LN)) indications. As the classification of
autoimmune kidney disease is becoming increasingly granular
and treatment approaches are being constantly refined, such data
are important to allow for more individualized recommendations
regarding prophylaxis strategies.org 2MATERIALS AND METHODS
Patient Population and Data Collection
The Austrian B-Cell Depletion Evaluation (ABCDE) study is
based on a multicenter retrospective data collection of adult
patients with immune-related kidney diseases, treated with at
least one course of RTX. Austrian tertiary centers for the
management of autoimmune kidney diseases were invited to
participate in this National Registry. From January 2015 until
December 2019 data on 144 patients from the participating
centers were collected.
The registry contains data from patients with any of the
following disorders: AAV, FSGS, immunoglobulin G4-related
disease (IgG4RD), LN, MCD, MN and membranoproliferative
glomerulonephritis (MPGN). Additional inclusion criteria
consisted of age ≥ 18 years at the start of RTX therapy and a
minimum follow-up time of 3 months after the first
RTX application.
Data on clinical characteristics, comorbidities, prior
immunosuppressives [i.e., calcineurin inhibitors (CNI),
cyclophosphamide (CYC), and mycophenolate mofetil (MMF)],
and baseline laboratory data of all patients were collected.
Additionally, detailed data on RTX application including dose,
treatment line, concomitant glucocorticoid treatment, and further
maintenance therapies, were gathered. Patients were treated with
RTX in accordance with their physician’s standard practice.
Dialysis was defined as newly started kidney replacement
therapy (KRT) after first RTX administration.
Serial measurements on immunoglobulin G (IgG) and
absolute neutrophil count (ANC) were conducted during the
observation period. Hypogammaglobulinemia and neutropenia
were classified by nadir IgG levels (IgG levels < 7 g/L) (5) and
ANC (neutrophil count <1.5 x 109/L) (defined by the local
laboratory) during the observation period. In addition, data on
occurrence of malignancies (solid tumors and malignant
hematological disorders) during RTX therapy were also recorded.
All data, if available, were derived retrospectively from the
electronic medical records of the attending centers. The date of
the first RTX application (index date) was registered to calculate
the time to outcome event. The duration of RTX therapy wasOctober 2021 | Volume 12 | Article 760708
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the drug or censored at the date of the last follow-up for patients
remaining on the drug at the time of data analysis. Data were
collected until patient death, loss of follow-up, or end of the
follow-up on 31 December 2019.
Definition of Infections and Outcomes
The NCI Common Terminology Criteria for Adverse Events
Version 5.0 (NCI-CTCAE v5.0) was used to define and grade
infections. Clinical and hospitalization reports were reviewed
during RTX treatment to identify severe (grade 3-5) infections.
Notably, mild infections (grade 1-2) were not considered. The
site of SI was defined as respiratory, gastrointestinal, urinary
tract, and other infections. Additionally, the daily corticosteroid
dose (prednisolone equivalent) at the time of infection
was collected.
The primary outcome of this study was the incidence of SI
within 12 months after the first RTX application. In addition,
incidence rates of hypogammaglobulinemia and neutropenia, as
well as new onset of malignancies, were also calculated.
Ethical Statement
The study protocol was approved by the institutional ethics
committee of the Medical Faculty of the Johannes Kepler
University, Linz, Austria (Nr. 1117/2018) and subsequently by
the local ethics committee of all participating centers. Informed
consent was not obtained from the participants, as it was a
noninterventional retrospective data analysis of real-life data
collected on patients’ regular visits. The study was conducted
under the principles of the Declaration of Helsinki.
Statistical Analysis
Continuous parameters are summarized as the median and
range (minimum, maximum) and categorical parameters are
presented as absolute and relative frequencies. Baseline
characteristics and investigated possible risk factors for SI at
start of RTX therapy included age, BMI, sex, creatinine level,
comorbidities, prior IS and RTX induction protocol are
presented for all patients, and for nephrotic (including MN,
MCD, FSGS) and nephritic (including AAV, LN, MPGN,
IgG4RD) patients separately. Missing specific data were not
imputed. Characteristics between both groups are compared by
Mann–Whitney U and Fisher’s exact test. To compare
incidences of SI between the groups and accounting for the
different baseline characteristics, inverse probability treatment
weighting (IPTW) was performed. The propensity score was
calculated by using logistic regression with group as outcome
and including age, BMI, sex, creatinine level, comorbidities (yes/
no) and prior IS (yes/no) as covariates. Additionally, Kaplan
Meier curves for 12-month SI are presented for nephrotic and
nephritic patients. To evaluate risk factors for SI within 12
months after RTX therapy start, univariable Cox proportional
hazard regression analyses were performed. Time to event is
defined as time from start of RTX to SI or death, lost to follow up
or month 12, whatever occurs first. In a multivariable Cox
regression model, all parameters with a p-value < 0.2 wereFrontiers in Immunology | www.frontiersin.org 3included. Results are presented as Hazard ratios (HR) and
their corresponding 95% confidence intervals (CIs). A p-value <
0.05 was considered statistically significant, and all analyses
were performed using SAS version 9.4 (SAS Institute, Cary,
NC, USA).RESULTS
Patient Characteristics
One hundred forty-four patients with autoimmune kidney
diseases were included. Detailed baseline demographic and
clinical characteristics are shown in Table 1. Eighty-three
patients had a nephritic glomerular disease, while 61 patients
belonged to the nephrotic group. The majority of patients had
AAV in the nephritic, while MN was the leading diagnosis in the
nephrotic group (54% and 33% of all patients, respectively). The
comorbidities were comparable in both groups. A significantly
higher baseline median creatinine was observed in the nephritic
group as compared to the nephrotic patients (1.7 [range: 0.7-
15.4] vs. 1.2 [range: 0.6-2.8] mg/dL, p<0.001) at the time of RTX
initiation. Nearly 40% of the patients in both groups received an
induction therapy protocol using 2 x 1000 milligram (mg) RTX a
fortnight apart or 4 x 375 mg/m2 in weekly intervals, respectively,
while fifty percent of all patients received RTX asmaintenance therapy.
Incidence Rate and Type of Severe
Infections
Twenty-five out of 144 patients (17.4%) presented with SI during
a median follow-up time of 2.2 (0-4.9) years. Respiratory
infections were the most frequent ones, but the majority of
patients (58% and 67% nephritic and nephrotic groups) had
other sites affected. The distribution of all SI according to the
infection sites is shown in Figure 1. Two patients had a SI of
grade 4 and 5 (n=1, respectively, both in nephritic group)
according to the CTCAE v5.0 criteria.
In the long term, patients in the nephritic group tended to
have more SI compared to nephrotic group patients (n=19,
22.9% vs. n=6, 10.2%; HR=1.82, 95% CI: 0.73-4.54, p=0.198).
The median time to the first SI was 139 (range: 17-1345) days.
Patients in the nephrotic group had a clearly shorter time until
experiencing their first infection as compared to those in the
nephritic group (median: 35 [range: 17-274] vs. 259 [range: 20-
1345] days, respectively; p=0.024).
Within 3 and 12 months after first RTX administration n=10
(7.0%) and n=17 (12.0%) SI were observed. For nephritic and
nephrotic patients, the infection rates were 6% versus 8.5%
within 3 months (HR=0.39, 95% CI: 0.10-1.51, p=0.172) and
13.3% versus 10.2% within 12 months (HR=0.91, 95% CI: 0.33-
2.51. p=0.852). Kaplan Meier estimates for 12-month SI rates are
presented in Figure 2.
Predictors of Severe Infections
Univariable Cox regression analysis assessed predictors
of SI within 12 months after first RTX administrationOctober 2021 | Volume 12 | Article 760708
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(hazard ratio [HR]: 0.88; 95% confidence interval [CI]: 0.79-
0.99; p=0.039) and baseline creatinine (HR: 1.25; 95% CI: 1.04-
1.49; p=0.017) significantly affected SI within 12 months after the
first RTX administration (Table 2).
All the patients in the nephritic group (n=19; 100%) who
experienced a SI after the first RTX administration received oral
corticosteroid (CS) treatment at the time of the infection. The
median dose of CS used at the time of infection was 7.5 (range:
2.5-50.0) mg. On the other hand, only two out of six (33%)
patients were treated with oral CS (median dose: 26.3 [range:




Hypogammaglobulinemia was observed in 72 out of 123 (58.5%)
patients with serum IgG measurements. Most of these periods
(40 out 72 [55.5%]) occurred within 12 months after the first
RTX administration. Nineteen patients had a SI and
hypogammaglobulinemia; however, no association between
hypogammaglobulinemia and SI was observed (p=0.067).
Interestingly, most of the infections (n=17) occurred before
hypogammaglobulinemia was observed.Frontiers in Immunology | www.frontiersin.org 4In total, 16 out of 140 (11.4%) patients with measurements
experienced neutropenia, and it was significantly associated with
SI during the whole observation period (p=0.030). Specifically,
nine episodes of neutropenia (n=5 and n=4 in the nephritic and
nephrotic groups, respectively) occurred during the first 12
months after the first RTX administration, which showed,
however, no association with SI neither in the nephritic nor in
the nephrotic group (p>0.05). Notably, no neutropenia was
observed at the time of the first RTX administration, while
only two patients were neutropenic at the time of the infection.
In addition, five patients (3.4%) experienced malignancy
during the observation period. Two patients had a skin tumor,
while one prostatic cancer, one breast cancer, and one malignant
testicular tumor were observed in the other three patients.DISCUSSION
The ABCDE Registry, an Austrian registry focusing on the use of
RTX in kidney disease indications, included 144 patients, with
the majority of patients having a diagnosis of AAV (54.2%) and
MN (33.3%). During the observational period, 25 patients
presented with a SI defined as CTCAE grade 3 and higher.
Among these, there was no significant difference betweenTABLE 1 | Baseline patient characteristics in the whole study population and stratified according to the classification on nephritic or nephrotic groups.
Whole study population
N = 144
Patients with nephritic diseases
N = 83
Patients with nephrotic diseases
N = 61
p-value
Age (years) 61.2 (20.4, 83.8) 65.1 (21.1, 83.8) 57.6 (20.4, 78.7) 0.012
BMI (kg/m2) 26.2 (17.7, 39.9) 25.6 (17.7, 37.6) 27.3 (19.9, 39.9) 0.036
Female sex, n (%) 51 (35.4) 39 (47.0) 12 (19.7) <0.001
Diagnosis, n (%)
AAV 78 (54.2) 78 (94.0) – –
LN 3 (2.1) 3 (3.6) – –
MPGN 1 (0.7) 1 (1.2) – –
IgG4RD 1 (0.7) 1 (1.2) – –
MN 48 (33.3) – 48 (78.7) –
MCD 8 (5.6) – 8 (13.1) –
FSGS 5 (3.5) – 5 (8.2) –
Comorbidities, n (%)
Pulmonary disease 12 (8.3) 7 (8.4) 5 (8.2) 1
Cardiovascular disease 30 (20.8) 15 (18.1) 15 (24.6) 0.408
Diabetes mellitus 17 (11.8) 9 (10.8) 8 (13.1) 0.795
Arterial hypertension 93 (64.6) 53 (63.9) 40 (65.6) 0.862
Dialysis (any time), n (%) 25 (17.4) 25 (30.1) 0 (0) <0.001
Creatinine (mg/dL)* 1.3 (0.6, 15.4) 1.7 (0.7, 15.4) 1.2 (0.6, 2.8) <0.001
Prior IS, n (%)
MMF 17 (11.8) 11 (13.3) 6 (9.8) 0.608
CNI 29 (20.1) 0 (0) 29 (47.5) <0.001
CYC 53 (36.8) 49 (59.0) 4 (6.6) <0.001
RTX induction protocol, n (%)
1000 mg
(2x/2-weeks apart)
62 (43.1) 34 (41.0) 28 (45.9) 0.001
375 mg/m2
(4x/weekly)
64 (44.4) 32 (38.6) 32 (52.5)
Other 18 (12.5) 17 (20.5) 1 (1.6)
RTX maintenance, n (%) 72 (50.0) 49 (59.0) 23 (37.7) 0.018October 2021 | Volume 12 | ArticleStatistically significant p-values appear in boldface type (p < 0.05). Continuous variables are expressed as median (minimum and maximum). Categorical variables are n (%). *Non-dialysis
dependent patients. AAV, anti-neutrophil cytoplasmatic antibody (ANCA), associated vasculitis; BMI, body mass index; CNI, calcineurin inhibitor; CYC, cyclophosphamide; FSGS, focal
segmental glomerulosclerosis; GN, glomerulonephritis; IgG4RD, immunoglobulin G4-related disease; IS, immunosuppression; LN, lupus nephritis; MCD, minimal change disease; MN,
membranous nephropathy; MMF, mycophenolate-mofetil; MPGN, membranoproliferative glomerulonephritis; RTX, rituximab.760708
Odler et al. Rituximab and Severe Infectionsnephritic and nephrotic glomerular diseases (22.9% versus
10.2%). Most infections occurred within the first 3 months of
RTX use, and this was most prominent for nephrotic diseases (5
infections out of 6 in total).Frontiers in Immunology | www.frontiersin.org 5This study found that for nephritic glomerular diseases the
risk of SI might be high when glucocorticoids are concomitantly
prescribed. All SI were recorded on background glucocorticoid
use. Reduced glucocorticoid regimens showed comparableFIGURE 2 | Kaplan-Meier curves for infection-free survival within the first 12 months after the first rituximab administration in patients with nephritic (blue line) and
nephrotic (red line) syndrome.FIGURE 1 | The distribution of all severe infections according to the infection sites in the nephritic and nephrotic groups.October 2021 | Volume 12 | Article 760708
Odler et al. Rituximab and Severe Infectionsefficacy estimates in AAV (6, 7). In the PEXIVAS trial, the
reduced-dose glucocorticoid regimen reached the primary end
point, a combination of end-stage kidney disease and death from
any cause, less frequently at one year of follow-up, although the
differences were not significant. However, a significant reduction
in SI at one year was observed with a reduction by over 30% in
comparison to a standard-dose glucocorticoid regimen (6). More
informative data on the use of a low-dose glucocorticoid regimen
in combination with RTX was recently provided by the LOVAS
trial, randomizing patients with AAV to either a reduced-dose or
high-dose glucocorticoid regimen. The cumulative glucocorticoid
dose was 1.3 g in the reduced-dose in comparison to 4.2 g in the
high-dose arm, corresponding to a reduction of 68%. A similar
proportion of patients achieved remission, while serious adverse
events were reduced in the reduced-dose arm. Notably, only 7 SI in
5 patients were recorded in the reduced-dose arm in comparison to
20 events in 13 patients in the high-dose glucocorticoid arm (7). In
the ABCDE Registry, fourteen of the 19 recorded SI in the nephritic
group occurred beyond 3 months of follow-up, and 8 after 12
months. Studies such as LOVAS or the RAVE trial with a prescribed
glucocorticoid withdrawal before month 6 after induction therapy
highlighted both the safety and efficacy of such an approach (7, 8).
A retrospective study from Germany subdivided patients by the use
of a glucocorticoid dose of either below 7.5 mg or greater/equal to
7.5 mg by month 6. Patients with a higher glucocorticoid dose had
more infectious episodes (1.7 versus 0.6), while the glucocorticoid
dose had no impact on patient survival, kidney function, or relapse
rate (9). The presented data of the ABCDE Registry also support a
paradigm change towards a reduced time of glucocorticoid use.
Notably, only 2 patients in the nephrotic group had concomitant
glucocorticoid therapy, which argues against a significant impact of
glucocorticoids on SI risk in this population.
Lower BMI (24.6 kg/m2 versus 26.9 kg/m2) was associated
with higher risk of SI. A recent study from Japan involving 93
patients with a diagnosis of microscopic polyangiitis (MPA)
subdivided patients into three groups, one group with low BMI
(<18.5 kg/m2, n=22), one group with normal BMI (18.5-23.0 kg/m2,
n=53) and one with high BMI (>23 kg/m2, n=18). SI were recorded
in 63.6%, 24.5% and 11.1% of patients in the respective groups.
Patients in the low and normal BMI group were more likely to
suffer from a body weight loss > 10% within six months before
diagnosis of MPA was made. Patients in the low and normal BMI
group also exhibited higher mortality rates in comparison to
patients in the high BMI group (10). Sub-analysis of the RAVE
trial indicated that newly diagnosed patients have an increase in
total and low-density lipoprotein cholesterol after achieving
remission. Reduced lipid levels at baseline correlated withFrontiers in Immunology | www.frontiersin.org 6erythrocyte sedimentation rate (11), indicating that inflammatory
processes may play a critical role explaining the initial weight loss
and altered lipid levels observed in patients with AAV. This
persistent inflammatory process may in part explain the higher
risk of SI observed in these patients. Lower BMI might also indicate
a higher disease severity and these patients might have received
higher glucocorticoid doses at baseline, again explaining the higher
risk of SI. Despite non-significant, patients with nephrotic
syndrome had a numerically lower frequency of SI, and water
retention/edema development leading to a higher BMI might also
influence our findings.
Most SI in our analysis occurred within the first months of
RTX administration, which is in line with several investigations.
A single-center study including 221 patients with autoimmune
indications found SI in 42 patients. The prevalence of infectious
complications was most pronounced within the first three
months of follow-up (7.2%) and increased to 15.5% at one and
17.8% at two years. Most patients presented with pneumonia
(45%) and/or bacteremia (21%) (12). RTX use for several
indications was associated with an increase in SI from 17.2% pre-
rituximab to 21.7% after administration among 8633 patients. Again,
most infections occurred within the first six months of RTX
administration. Pre-existing hypogammaglobulinemia was a strong
risk factor for SI before RTX initiation and a third of these patients
experienced SI following RTX (13). Hypogammaglobulinemia was
frequently observed in our cohort (72 out of 123 with measurements,
58.5%), but was not associated with SI in our study. Notably, the
sample size might have impacted this finding. Another complication
of RTX is late-onset neutropenia (14). Neutropenia was associated
with SI in our analysis of the ABCDE Registry, as 8 out of 16 patients
with neutropenia had a SI during follow-up. A large single-center
study found at least one episode of late-onset neutropenia in 71/738
adult patients receiving RTX. Its occurrence is more frequent within
the first year of RTX administration and is not observed in patients
withminimal change disease or focal segmental glomerulosclerosis. A
majority of patients was asymptomatic during the neutropenic
episode, while 31.3% and 8.5% presented with fever and
septicemia (15).
Further analyses revealed an association of baseline creatinine
with the risk of SI, which remained significant after adjustment
for dialysis-dependency. Similar results were reported from a
French study focusing on a combined end point of infection and/
or death. Twenty-six out of 98 patients reached the end point
during follow-up and baseline creatinine showed a borderline
significance (4). Baseline creatinine was comparable to our
cohort. Most analyses focusing on patients with AAV found a
similar tendency towards more SI in patients with impaired
kidney function (16–20), which is in line with our results.
Infections are one of the leading complications of nephrotic
syndrome. Our analysis indicated that patients with nephrotic
syndrome are prone to infections particularly within the first
three months after RTX administration. In MN, there is an
increased risk to develop invasive pneumococcal infection and
there is a recommendation that patients receive pneumococcal
and annual influenza vaccination (21). Vaccination might
mitigate the risk to develop severe courses of these infections,
while the humoral response to vaccines is severely impaired byTABLE 2 | Multivariable Cox regression analysis on the predictors of severe
infections within 12 months after the first rituximab administration.
Covariate Hazard ratio 95% confidence interval p-value
BMI (kg/m2) 0.88 0.79-0.99 0.039
Creatinine (mg/dL) 1.25 1.05-1.49 0.017
Dialysis 0.90 0.22-3.76 0.887
Arterial hypertension 2.40 0.65 – 8.86 0.189Statistically significant p-values appear in boldface type (p < 0.05). BMI, body mass index.October 2021 | Volume 12 | Article 760708
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with trimethoprim/sulfamethoxazole, known to reduce SI in
patients with AAV (17, 23), might be used in this vulnerable phase.
This study has several limitations. The ABCDE Registry was
initiated as a retrospective survey among nephrology departments
to capture complications of RTX therapy in glomerular diseases,
before initiating a prospective study phase. The analyzed groups
(nephritic and nephrotic) differed significantly in terms of age,
BMI, sex, the history of immunosuppressive drug use and
maintenance RTX administration, some of these factors
potentially influencing our results. The presented study assessed
data retrospectively, so limitations inherent with its retrospective
character need to be considered (i.e. missing data, such as
information on IgG levels). Initial data collection did not
include the assessment of antibiotic prophylaxis used in these
patients (i.e. Pneumocystis jirovecii prophylaxis). This information
would be of particular interest in patients with nephrotic syndrome
presenting with SI early after RTX use. Information about cumulative
glucocorticoid use, the use of intravenous methylprednisolone to
control initial disease activity and longitudinal follow-up of BMI
values is missing, all of particular importance to understand the
finding of a higher rate of SI in patients with lower BMI. The sample
size of our study is small, but comparable to other investigations
published, and multi-national efforts are needed to inform about
frequency, severity and risk factors of SI in patients with glomerular
diseases receiving rituximab.
In conclusion, analysis of the ABCDE Registry retained
impaired kidney function and lower BMI as independent risk
factors to develop SI after RTX administration. All infectious
complications in patients with nephritic glomerular diseases
occurred during concomitant GC treatment, while the risk
might be independent of glucocorticoid use in nephrotic
patients. Further studies are needed assessing the exact use of
antibiotic prophylaxis, the capacity of antibiotics to mitigate the
risk of SI, and the role of low-dose glucocorticoid protocols and
influence on SI.Frontiers in Immunology | www.frontiersin.org 7DATA AVAILABILITY STATEMENT
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